Spyre Historical Cash Flow
| SYRE Stock | 26.44 0.05 0.19% |
Analysis of Spyre Therapeutics cash flow over time is an excellent tool to project Spyre Therapeutics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Other Non Cash Items of 228.6 M or Capital Expenditures of 0.0 as it is a great indicator of Spyre Therapeutics ability to facilitate future growth, repay debt on time or pay out dividends.
Spyre |
About Spyre Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Spyre balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Spyre's non-liquid assets can be easily converted into cash.
Spyre Therapeutics Cash Flow Chart
Add Fundamental
Change In Working Capital
The difference in the amount of working capital from one period to the next, indicating the change in a company's short-term assets and liabilities.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Depreciation
Depreciation indicates how much of Spyre Therapeutics value has been used up. For tax purposes Spyre Therapeutics can deduct the cost of the tangible assets it purchases as business expenses. However, Spyre Therapeutics must depreciate these assets in accordance with IRS rules about how and when the deduction may be taken, and how long it will last. The systematic allocation of the cost of a tangible asset over its useful life.Most accounts from Spyre Therapeutics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Spyre Therapeutics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spyre Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Spyre Stock refer to our How to Trade Spyre Stock guide.At present, Spyre Therapeutics' Begin Period Cash Flow is projected to increase significantly based on the last few years of reporting. The current year's Other Cashflows From Financing Activities is expected to grow to about 201.6 M, whereas Change In Working Capital is projected to grow to (4.9 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Other Non Cash Items | 90K | 823K | 217.7M | 228.6M | Depreciation | 1.6M | 1.6M | 744K | 888.0K |
Spyre Therapeutics cash flow statement Correlations
Click cells to compare fundamentals
Spyre Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Spyre Therapeutics cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (3.2M) | 71.2M | (75.0M) | 19.4M | 152.8M | 160.4M | |
| Free Cash Flow | (67.2M) | (80.1M) | (54.3M) | (80.2M) | (99.9M) | (94.9M) | |
| Change In Working Capital | 7.1M | (2.5M) | 1.8M | (5.5M) | (5.2M) | (4.9M) | |
| Begin Period Cash Flow | 22.5M | 20.8M | 91.9M | 17.0M | 36.4M | 38.3M | |
| Other Cashflows From Financing Activities | (1.7M) | 816K | 1.9M | 222K | 192.0M | 201.6M | |
| Depreciation | 901K | 996K | 1.6M | 1.6M | 744K | 888.0K | |
| Other Non Cash Items | 3.8M | 619K | 90K | 823K | 217.7M | 228.6M | |
| Capital Expenditures | 422K | 1.5M | 4.3M | 573K | 38K | 0.0 | |
| Total Cash From Operating Activities | (65.7M) | (75.8M) | (53.7M) | (80.1M) | (99.9M) | (94.9M) | |
| Net Income | (78.3M) | (80.9M) | (65.8M) | (83.8M) | (338.8M) | (321.9M) | |
| Total Cash From Financing Activities | 65.7M | 154.5M | 1.4M | 42.7M | 361.1M | 379.1M | |
| End Period Cash Flow | 19.3M | 91.9M | 17.0M | 36.4M | 189.2M | 198.7M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Spyre Therapeutics is a strong investment it is important to analyze Spyre Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Spyre Therapeutics' future performance. For an informed investment choice regarding Spyre Stock, refer to the following important reports:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spyre Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Spyre Stock refer to our How to Trade Spyre Stock guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spyre Therapeutics. If investors know Spyre will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spyre Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (37.90) | Return On Assets (0.39) | Return On Equity (0.92) |
The market value of Spyre Therapeutics is measured differently than its book value, which is the value of Spyre that is recorded on the company's balance sheet. Investors also form their own opinion of Spyre Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Spyre Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spyre Therapeutics' market value can be influenced by many factors that don't directly affect Spyre Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Spyre Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spyre Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spyre Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.